You are here: Industry Insights > Nafamostat

News List

“At Home Coronavirus Pill” to Advance to Phase 2 Clinical Development americanpharmaceuticalreview
May 08, 2021
Ensysce Biosciences, Inc. announced that Ensysce’s subsidiary, Covistat, will be presenting at the upcoming American Thoracic Society (ATS) Annual Meeting to be held May 14-19, 2021.
Preclinical Study Finds Nafamostat Blocks SARS-CoV-2 Infection in Human Lung Cells americanpharmaceuticalreview
August 24, 2020
A preclinical study testing the generic drug nafamostat in human cells shows it can help block SARS-CoV-2 infection.
Daiichi Sankyo to develop Nafamostat inhalation therapy for Covid-19 pharmaceutical-technology
June 10, 2020
Japanese pharmaceutical company Daiichi Sankyo has signed a basic agreement with the University of Tokyo, Nichi-Iko Pharmaceutical and RIKEN for the research and development (R&D) of a Nafamostat inhalation formulation to treat Covid-19.
Sun Pharma gets DCGI nod for clinical trial with Nafamostat in COVID-19 patients expresspharma
June 01, 2020
Nafamostat is identified as a potential candidate for COVID-19 patients by scientists at the University of Tokyo and Leibniz Institute for Primate Research, Germany.
Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19) worldpharmanews
March 31, 2020
Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19). The University of Tokyo anno